A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients. / Rasmussen, Jacob H; Håkansson, Katrin; Rasmussen, Gregers B; Vogelius, Ivan R; Friborg, Jeppe; Fischer, Barbara M; Bentzen, Søren M; Specht, Lena.

I: Oral Oncology, Bind 81, 2018, s. 52-60.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Rasmussen, JH, Håkansson, K, Rasmussen, GB, Vogelius, IR, Friborg, J, Fischer, BM, Bentzen, SM & Specht, L 2018, 'A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients', Oral Oncology, bind 81, s. 52-60. https://doi.org/10.1016/j.oraloncology.2018.04.009

APA

Rasmussen, J. H., Håkansson, K., Rasmussen, G. B., Vogelius, I. R., Friborg, J., Fischer, B. M., Bentzen, S. M., & Specht, L. (2018). A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients. Oral Oncology, 81, 52-60. https://doi.org/10.1016/j.oraloncology.2018.04.009

Vancouver

Rasmussen JH, Håkansson K, Rasmussen GB, Vogelius IR, Friborg J, Fischer BM o.a. A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients. Oral Oncology. 2018;81:52-60. https://doi.org/10.1016/j.oraloncology.2018.04.009

Author

Rasmussen, Jacob H ; Håkansson, Katrin ; Rasmussen, Gregers B ; Vogelius, Ivan R ; Friborg, Jeppe ; Fischer, Barbara M ; Bentzen, Søren M ; Specht, Lena. / A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients. I: Oral Oncology. 2018 ; Bind 81. s. 52-60.

Bibtex

@article{7d77e4763b9a45c6b19e5f714ae3a10b,

title = "A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients",

abstract = "OBJECTIVES: A previously published prognostic model in patients with head and neck squamous cell carcinoma (HNSCC) was validated in both a p16-negative and a p16-positive independent patient cohort and the performance was compared with the newly adopted 8th edition of the UICC staging system.MATERIALS AND METHODS: Consecutive patients with HNSCC treated at a single institution from 2005 to 2012 were included. The cohort was divided in three. 1.) Training cohort, patients treated from 2005 to 2009 excluding patients with p16-positive oropharyngeal squamous cell carcinomas (OPSCC); 2.) A p16-negative validation cohort and 3.) A p16-positive validation cohort. A previously published prognostic model (clinical model) with the significant covariates (smoking status, FDG uptake, and tumor volume) was refitted in the training cohort and validated in the two validation cohorts. The clinical model was used to generate four risk groups based on the predicted risk of disease recurrence after 2 years and the performance was compared with UICC staging 8th edition using concordance index.RESULTS: Overall 568 patients were included. Compared to UICC the clinical model had a significantly better concordance index in the p16-negative validation cohort (AUC = 0.63 for UICC and AUC = 0.73 for the clinical model; p = 0.003) and a borderline significantly better concordance index in the p16-positive cohort (AUC = 0.63 for UICC and 0.72 for the clinical model; p = 0.088).CONCLUSION: The validated clinical model provided a better prognostication of risk of disease recurrence than UICC stage in the p16-negative validation cohort, and similar prognostication as the newly adopted 8th edition of the UICC staging in the p16-positive patient cohort.",

author = "Rasmussen, {Jacob H} and Katrin H{\aa}kansson and Rasmussen, {Gregers B} and Vogelius, {Ivan R} and Jeppe Friborg and Fischer, {Barbara M} and Bentzen, {S{\o}ren M} and Lena Specht",

year = "2018",

doi = "10.1016/j.oraloncology.2018.04.009",

language = "English",

volume = "81",

pages = "52--60",

journal = "Oral Oncology Extra",

issn = "1741-9409",

publisher = "Pergamon Press",

}

RIS

TY - JOUR

T1 - A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients

AU - Rasmussen, Jacob H

AU - Håkansson, Katrin

AU - Rasmussen, Gregers B

AU - Vogelius, Ivan R

AU - Friborg, Jeppe

AU - Fischer, Barbara M

AU - Bentzen, Søren M

AU - Specht, Lena

PY - 2018

Y1 - 2018

N2 - OBJECTIVES: A previously published prognostic model in patients with head and neck squamous cell carcinoma (HNSCC) was validated in both a p16-negative and a p16-positive independent patient cohort and the performance was compared with the newly adopted 8th edition of the UICC staging system.MATERIALS AND METHODS: Consecutive patients with HNSCC treated at a single institution from 2005 to 2012 were included. The cohort was divided in three. 1.) Training cohort, patients treated from 2005 to 2009 excluding patients with p16-positive oropharyngeal squamous cell carcinomas (OPSCC); 2.) A p16-negative validation cohort and 3.) A p16-positive validation cohort. A previously published prognostic model (clinical model) with the significant covariates (smoking status, FDG uptake, and tumor volume) was refitted in the training cohort and validated in the two validation cohorts. The clinical model was used to generate four risk groups based on the predicted risk of disease recurrence after 2 years and the performance was compared with UICC staging 8th edition using concordance index.RESULTS: Overall 568 patients were included. Compared to UICC the clinical model had a significantly better concordance index in the p16-negative validation cohort (AUC = 0.63 for UICC and AUC = 0.73 for the clinical model; p = 0.003) and a borderline significantly better concordance index in the p16-positive cohort (AUC = 0.63 for UICC and 0.72 for the clinical model; p = 0.088).CONCLUSION: The validated clinical model provided a better prognostication of risk of disease recurrence than UICC stage in the p16-negative validation cohort, and similar prognostication as the newly adopted 8th edition of the UICC staging in the p16-positive patient cohort.

AB - OBJECTIVES: A previously published prognostic model in patients with head and neck squamous cell carcinoma (HNSCC) was validated in both a p16-negative and a p16-positive independent patient cohort and the performance was compared with the newly adopted 8th edition of the UICC staging system.MATERIALS AND METHODS: Consecutive patients with HNSCC treated at a single institution from 2005 to 2012 were included. The cohort was divided in three. 1.) Training cohort, patients treated from 2005 to 2009 excluding patients with p16-positive oropharyngeal squamous cell carcinomas (OPSCC); 2.) A p16-negative validation cohort and 3.) A p16-positive validation cohort. A previously published prognostic model (clinical model) with the significant covariates (smoking status, FDG uptake, and tumor volume) was refitted in the training cohort and validated in the two validation cohorts. The clinical model was used to generate four risk groups based on the predicted risk of disease recurrence after 2 years and the performance was compared with UICC staging 8th edition using concordance index.RESULTS: Overall 568 patients were included. Compared to UICC the clinical model had a significantly better concordance index in the p16-negative validation cohort (AUC = 0.63 for UICC and AUC = 0.73 for the clinical model; p = 0.003) and a borderline significantly better concordance index in the p16-positive cohort (AUC = 0.63 for UICC and 0.72 for the clinical model; p = 0.088).CONCLUSION: The validated clinical model provided a better prognostication of risk of disease recurrence than UICC stage in the p16-negative validation cohort, and similar prognostication as the newly adopted 8th edition of the UICC staging in the p16-positive patient cohort.

U2 - 10.1016/j.oraloncology.2018.04.009

DO - 10.1016/j.oraloncology.2018.04.009

M3 - Journal article

C2 - 29884414

VL - 81

SP - 52

EP - 60

JO - Oral Oncology Extra

JF - Oral Oncology Extra

SN - 1741-9409

ER -

ID: 212954852